Baylor College of Medicine Cancer Center

贝勒医学院癌症中心

• 批准号: 9121003
• 负责人: C KENT OSBORNE
• 金额: $ 11.22万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-01 至 2020-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9121003
• 关键词: Basic Science; Bioinformatics; Biological; Biological Markers; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Etiology; Catchment Area; Clinic; Clinical; Clinical Research; Communities; Community Outreach; Comprehensive Cancer Center; Computational Biology; Country; County; Data; Development; Diagnosis; Diagnostic; Disease; Early Diagnosis; Education; Funding; Future; Genetically Engineered Mouse; Genomics; Geographic Locations; Goals; Growth; Human; Immunotherapy; In Vitro; Institutes; Institution; Interdisciplinary Study; Laboratories; Malignant Childhood Neoplasm; Malignant Neoplasms; Measures; Medicine; Mission; Molecular Genetics; Morbidity - disease rate; Mutation; NCI-Designated Cancer Center; Neoplasm Metastasis; Nuclear Receptors; Outcome; Pathway interactions; Patient Care; Patients; Peer Review; Physicians; Population Heterogeneity; Population Sciences; Professional Education; Proteomics; Publications; Reagent; Research; Research Infrastructure; Research Personnel; Research Support; Resource Sharing; Role; Scientist; Signal Pathway; Signal Transduction; Texas; Therapeutic; Translating; Translational Research; Translations; United States; United States National Institutes of Health; Vision; Xenograft procedure; cancer education; cancer initiation; cancer therapy; clinical care; clinically relevant; college; functional genomics; genome integrity; improved; malignant breast neoplasm; member; metabolomics; mortality; mouse model; multidisciplinary; next generation; novel strategies; novel therapeutics; pre-clinical; prevent; programs; therapeutic development; therapy development; transcriptomics; validation studies

 DESCRIPTION (provided by applicant): The overarching goal of the Cancer Biology Program, CBP, is to increase our understanding of the basic genetic, molecular, and biological mechanisms of cancer development and progression and to facilitate the translation of these findings for improved diagnostic, therapeutic, and preventative measures. The CBP consists of 51 Research Members, 14 Clinical Members, and 2 Adjunct Members. The membership spans 14 departments, and 2 centers, with two members from other institutions. The membership has $4.5 million in NCI funded research support out of a total of $30.6 million in total research support. The CBP program is highly productive with a total of 685 publications with 15% of the publications being intra-programmatic and 19% inter-programmatic. The program has been subdivided into 4 interdependent themes: Computational Biology, Functional Genomics, Cell Signaling, and Translation. The Computational Theme uses bioinformatic analyses of genomic, transcriptomic, proteomic, and metabolomic data to identify clinically relevant pathways for the development of therapeutic reagents or potential biomarkers to be moved to preclinical validation studies. The Functional Genomics Theme uses genetically engineered mouse models and patient-derived xenograft analysis to determine the significance of genetic alterations in human cancer as identified by the Computational Biology Theme. The Cell Signaling Theme functions to conduct in vitro mechanistic analysis of signaling pathways identified by the Computational and Functional Genomics Theme to determine how these pathways regulate cancer initiation, progression, and metastasis. The role of this group is to identify which pathways are targets for biomarkers or therapeutic development. Finally, the Translational Theme consists of clinical researchers and researchers involved in development of novel therapeutics. The goal of this Theme is to facilitate the translation of the basic science findings of the CBP to the patient. This group aids CBP researchers in determining how these findings can be translated to the development of therapies and biomarkers for the treatment of cancer.

 描述（由申请人提供）：癌症生物学计划 (CBP) 的总体目标是增进我们对癌症发生和进展的基本遗传、分子和生物学机制的理解，并促进将这些发现转化为改进的诊断、治疗和预防措施。 CBP 由 51 名研究成员、14 名临床成员和 2 名兼职成员组成。成员涵盖 14 个部门和 2 个中心，其中两名成员来自其他机构。在总共 3060 万美元的研究支持总额中，会员获得了 450 万美元的 NCI 资助的研究支持。 CBP 计划成效显着，共有 685 份出版物，其中 15% 是计划内出版物，19% 是计划间出版物。该项目被细分为 4 个相互依赖的主题：计算生物学、功能基因组学、细胞信号传导和翻译。计算主题使用基因组、转录组、蛋白质组和代谢组数据的生物信息学分析来确定临床相关途径，用于开发治疗试剂或潜在生物标志物，并将其转移到临床前验证研究。功能基因组学主题使用基因工程小鼠模型和患者来源的异种移植物分析来确定计算生物学主题所确定的人类癌症中基因改变的重要性。细胞信号传导主题的功能是对计算和功能基因组学主题确定的信号传导途径进行体外机制分析，以确定这些途径如何调节癌症的发生、进展和转移。该小组的作用是确定哪些途径是生物标志物或治疗开发的目标。最后，转化主题由临床研究人员和参与新型疗法开发的研究人员组成。该主题的目标是促进基础科学发现的转化 CBP 向患者提供的信息。该小组帮助 CBP 研究人员确定如何将这些发现转化为癌症治疗疗法和生物标志物的开发。